Based on REDEFINE trial populations and the NDA submission terms, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea Adults 18 years or older Not pregnant or breastfeeding Contraindications will likely include: personal or family history of MTC or MEN 2 syndrome, prior serious allergic reaction to semaglutide or cagrilintide, and active pancreatitis
Although overexpression of isoforms such as ALOX5, ALOX12, and ALOX15 can sensitize cells to ferroptosis (Yang et al., 2022), none of the isoforms has yet been proven to play a decisive role in ferroptosis
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Robb Bird, NMD FAARM Medical Director, Transformyou
Vieira SR
It can also help protect the skin from environmental stressors like UV rays and pollution